Arianna F.
- Country
- Italy
- Department
- Oncology
Research Overview
Data & Insights
Has run more than one trial at 15 of 136 partner sites.
Specializations
Lung Cancer
The investigator concentrates on advanced Non-Small Cell Lung Cancer across molecular sub‑groups, including ALK‑positive, EGFR‑mutated, KRAS G12C‑driven and HER2‑mutated disease, addressing both metastatic and adjuvant contexts.
- Advanced Non-Small Cell Lung Cancer
- ALK-positive lung carcinoma
- EGFR-mutated NSCLC
- KRAS G12C driven lung cancer
- HER2-mutated lung tumors
Research activities span targeted therapy selection, resistance mechanisms and integration of immuno‑oncology approaches.
Breast Cancer
Focus is placed on heterogeneous breast malignancies, ranging from HER2‑positive and HER2‑low disease to hormone‑receptor positive/HER2‑negative and triple‑negative subtypes, with particular attention to endocrine‑resistant and post‑CDK4/6 inhibitor settings.
- HER2-positive breast cancer
- HER2-low disease
- ER-positive/HER2-negative advanced breast cancer
- Triple‑negative breast cancer
- Hormone receptor positive disease with CDK4/6 inhibitor resistance
Efforts include novel antibody‑drug conjugates, HER2‑targeted strategies and combination endocrine‑immunotherapy regimens.
Gynecologic Oncology
Research addresses high‑risk gynecologic malignancies, emphasizing molecularly defined ovarian, fallopian tube, primary peritoneal and endometrial cancers, as well as PD‑L1‑selected cervical disease.
- High‑grade serous ovarian cancer
- Endometrial cancer
- Fallopian tube carcinoma
- Primary peritoneal carcinoma
- Cervical cancer with PD‑L1 expression
Clinical work integrates PARP inhibition, anti‑angiogenic agents and immune checkpoint modulation.
Hematologic Malignancies
Investigator activity covers both lymphoid and myeloid disorders, including aggressive leukemias, diverse lymphoma subtypes and plasma‑cell neoplasms.
- Acute Myeloid Leukemia
- Diffuse Large B‑Cell Lymphoma
- Follicular Lymphoma
- Multiple Myeloma
- Hodgkin lymphoma
Therapeutic focus includes targeted agents, bispecific antibodies and novel immunomodulatory combinations.
Urologic & Renal Cancers
The portfolio includes advanced prostate disease, renal cell carcinoma and urothelial malignancies, targeting both hormone‑sensitive and castration‑resistant states.
- Metastatic Castration‑Resistant Prostate Cancer
- Renal cell carcinoma
- Urothelial carcinoma
- High‑risk localized prostate cancer
- Metastatic bladder cancer
Key investigations involve androgen‑axis inhibitors, checkpoint blockade and antibody‑drug conjugates.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.